Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- Annual Price Revisions of All Drugs Unacceptable: JMA Chief
December 1, 2016
- Japan, US, Europe Trade Groups Vehemently Oppose Annual Price Revisions
December 1, 2016
- JGA Rebuts Govt Panel Members’ Pricing Reform Proposals in Emergency Statement
November 30, 2016
- Drug Pricing Rules Should Be Fundamentally Reviewed: JMA Chief
November 28, 2016
- EFPIA, PhRMA “Regret” Out-of-Cycle Price Slash for Opdivo
November 22, 2016
- EFPIA Japan Lauds MHLW Task Force’s Proposal on Blood Products and Vaccines Industries
November 22, 2016
- JPMA to Straighten Up Industry Positions on FY2018 Pricing Reform
November 18, 2016
- Opdivo Price Cut “Unavoidable” to Maintain Universal Healthcare: JMA Chief
November 18, 2016
- FPMAJ, JPMA Issue Joint Statement on Emergency Price Cut for Opdivo
November 17, 2016
- Drug Costs Is Main Culprit of Ballooning Medical Spending: Hodanren
November 16, 2016
- Japan Society of Generic Medicines Calls for Lawmaker-Sponsored Bill to Push Biosimilar Use
November 14, 2016
- PhRMA, EFPIA Members Conducted 825 Japan Clinical Trials in 2015
November 8, 2016
- Japan Biosimilar Association Draws Gradual Rise in Membership, Mixed Interests
November 7, 2016
- Realtor-Led Tokyo Life Sciences Hub Initiative Aims to Fill Void between Academia, Pharmas
October 27, 2016
- Japan Should Adopt French-Type HTA: JMA Exec Suzuki
October 26, 2016
- No Plan to Respond to MHLW Task Force’s Proposal on Vaccine, Blood Product Industries: JPMA
October 21, 2016
- Keidanren Wades into Pricy Med Debate, Calls for Quick Price Review
October 17, 2016
- Govt and Industry Should Generate Ideas Together: EFPIA Japan Chief
October 7, 2016
- Value of Pharmaceutical Innovation Should Be Fully Recognized: PhRMA CEO
September 30, 2016
- Generic Use Rate at 60.1% in April-June: JGA
September 30, 2016
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…